DAVID P. LUCI - 06 Jan 2025 Form 4 Insider Report for Acurx Pharmaceuticals, Inc. (ACXP)

Role: President and CEO, Director, 10%+ Owner
Signature: /s/ Kostantinos Skordalos, Power of Attorney For: David P. Luci
Issuer symbol: ACXP
Transactions as of: 06 Jan 2025
Net transactions value: +$50,000
Form type: 4
Filing time: 08 Jan 2025, 16:31:33 UTC
Previous filing: 03 Apr 2024
Next filing: 06 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACXP	Common Stock	Purchase	$50,000	+49,261	+4.7%	$1.02	1,097,458	06 Jan 2025	Direct	F1
holding	ACXP	Common Stock						15,083	06 Jan 2025	By spouse
holding	ACXP	Common Stock						35,000	06 Jan 2025	By child

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACXP	Warrants for Common Stock	Purchase	$0	+49,261		$0.000000	49,261	06 Jan 2025	Common Stock	49,261	$0.9000	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.
F2	Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.